Introduction
RNA interference (RNAi) was discovered about 10 years ago and has become a standard widely used method for silencing the expression of any target gene of interest (3) . Target gene silencing is mediated by small interfering RNAs (siRNAs; double stranded RNA molecules 19-25 nucleotides in length), which trigger a catalytic mechanism for mRNA degradation. siRNA is unstable and has poor cellular uptake due to its physiochemical and biological properties. To increase the stability of siRNA and improve its uptake into cells, scientific companies have designed siRNA modifications and/or developed a variety of in vitro delivery agents.
Pancreatic stellate cells (PSCs) are now considered therapeutic targets in pancreatic cancer and chronic pancreatitis. Delivery of siRNA into PSCs provides a valuable tool for selectively silencing genes to examine their cellular function. Several factors can influence the degree to which a target gene is silenced in vitro including: 1) transfection efficiency; 2) transcription rate of the target gene; 3) protein stability and turnover; 4) efficacy of the siRNA sequence; and 5) growth characteristics of the cells. Primary cultures of cells can be difficult to transfect. The following method has taken all these factors into account and has been optimised for highly efficient delivery of siRNA into primary cultures of PSCs. The example which will be illustrated is transfection of rat PSCs with HSP90 specific siRNA using lipofectamine™ 2000. 
Materials/Reagents/Equipment

Methods
Isolation of rat pancreatic stellate cells
Isolation of rat PSCs is performed by density gradient centrifugation using a method developed by Apte et al (2) . Briefly, excised pancreatic tissue is digested with proteases and DNAse and the digest centrifuged through a 11.4 % w/v Nycodenz gradient for 20 minutes at 1400 g. Stellate cells are harvested and resuspended in IMDM containing 10% FBS, 4 mM glutamine and penicillin / streptomycin 1% v/v. Cells are cultured at 37°C in a humidified 5% CO 2 / air atmosphere. Purity of freshly isolated PSCs is assessed by dual staining of cells for the presence of lipid droplets in the cytoplasm and for glial fibrillary acidic protein (GFAP). Upon culture on plastic, activated PSCs were identified by immunostaining for -smooth muscle actin ( -SMA) as described previously (2) . Transfection of activated PSCs is performed with siRNA as described below (Section 2.3).
siRNA resuspension
ON-TARGET plus siRNA pool is used because it contains a pool of four individual siRNA sequences for the target gene (Note 1). The main advantages of using a pool of siRNA are 1) lower concentration of siRNA can be used, reducing off target effects; and 2) at least one of the 4 siRNA sequences is guaranteed to provide silencing of the target gene. To prepare siRNA use the following steps:
1. Briefly centrifuge the tube containing the siRNA to ensure that the siRNA pellet is at the base of the tube. 5. During this incubation, remove the cell medium containing 10% serum from the cells and wash the cells with 1x Opti-MEM followed by addition of 1ml of Opti-MEM and incubation for 20 minutes.
Transfection of PSCs with siRNA
6. Add 880μl of Opti-MEM to the siRNA/nonsilencing RNA + L2K solutions (Final concentration is 100nM, Note 3), mix well with a pipette and add 1ml of the appropriate transfection complex into the dedicated well.
For each transfection, a mock no transfection control (L2K only) is included (Note 4).
7. Incubate cells with the transfection complex for 5 hours.
8. At the end of this period, replace medium with fresh IMDM containing 10% serum (without antibiotics).
9. mRNA and protein levels are assessed after 72 hours (Note 5) using real-time PCR and western blotting.
Uptake of siRNA labelled with Alexa Fluor-488
Rat PSCs were treated as above (section 2.3) with lipofectamine alone, siRNA alone (100nM; Alexa Fluor-488) or lipofectamine + siRNA (100nM; Alexa Fluor-488) for 5 hours and cellular uptake is assessed after 24 hours by flow cytometry and confocal microscopy.
With this protocol, siRNA (Alexa fluor-488) uptake using lipofectamine as the transfection vehicle was 67.2% (Fig 1A and 1B) . Confocal microscopy also demonstrated delivery of siRNA to perinuclear regions of the cytoplasm which is typical for siRNA transfection. Once inside the cell siRNA is first localised to the cytoplasm and then released from L2K to enter the RNAi machinery to enable the silencing of its target gene (Fig 1C) . Note 6. 2. Lysates are then added onto a QIA shredder spin column which is placed into a 2ml collection tube and centrifuged for 2 minutes at >8000g.
3. The homogenised lysate in the collection tube is then transferred to a genomic DNA eliminator spin column in a 2 ml collection tube and centrifuged for at >8000g for 30 seconds.
4. RNA is then extracted using the RNeasy Plus Mini Kit as per the manufacturers instructions (Qiagen).
5
. RNA content is then estimated using a Nanodrop spectrophotometer. RNA samples are stored at -80 C until required.
2.6
Real-time PCR to assess mRNA silencing capacity of HSP90 siRNA Rat PSCs (n=3) were transfected with either L2K alone (mock), non-silencing siRNA (100nM) or HSP90 specific siRNA (100nM) and HSP90 mRNA levels were assessed at 72 hours posttransfection. Figure 2A demonstrates that transfection of rat PSCs with HSP90 specific siRNA resulted in >75% silencing of HSP90 mRNA levels at 72 hours post-transfection. Similar results were obtained as early as 48 hours after transfection (data not shown). We have demonstrated significant silencing using this technique with more than ten specific siRNA seqences, including TLR4 (4). Representative western blots for HSP90 and GAPDH 72 hours post-transfection. C) HSP90 siRNA significantly reduced HSP90 protein levels as indicated by the graph of densitometry data of western blots (C; *p<0.05 vs mock and ns-siRNA, n=3 separate PSC preparations). In contrast GAPDH was not affected by the HSP90 siRNA. Rat PSCs (n=3) were transfected with either L2K alone (mock), non-silencing siRNA (100nM) or HSP90 specific siRNA (100nM) and HSP90 protein expression was assessed at 72 hours post-transfection. Figure 2B demonstrates that HSP90 siRNA significantly decreased HSP90 protein expression by rat PSCs by more than 90% (Fig 2C) . GAPDH was unaffected by the siRNA treatment.
Western
Notes
1. I prefer to use Dharmacon's ON-TARGET plus siRNA, however, there are several other reputable suppliers of siRNA including Qiagen and Invitrogen.
2. This siRNA transfection protocol has been optimised for cells cultured in a 6-well plate.
However, post-transfection the cells can be harvested and reseeded into other plateformats (i.e. 96-well plates, migration chambers etc) for functional studies.
3. In most cases, the optimal dose of siRNA should be between 25-100nM. Each new siRNA sequence should be titrated and gene silencing assessed. All future experiments should use the lowest dose of siRNA which provides the maximal knockdown of the target gene.
4. It is important to always include a mock no transfection control in each assay (i.e. cells transfected with lipofectamine alone) and a non-silencing siRNA as an additional control. Make sure that if you are using a pool of siRNA (i.e. 4 siRNA sequences, as above) to use the appropriate pooled non-silencing control.
5. It is important to perform a time course study when initially testing a new target siRNA sequence. Test gene silencing capacity at 24h, 48h, 72h and 96h post-transfection. This will provide essential data on the time point which corresponds to maximal knockdown of the target gene and also the duration of knockdown.
6. This method has also been successfully used to transfect human cancer-associated PSCs with siRNA, as well as several pancreatic cancer cell lines (MiaPaCa-2, Panc-1, HPAF-II and ASPC-1) (1).
